Analysts suggest “buy” on CVS
Analysts maintain a positive outlook on CVS Health (CVS) stock. CVS Health’s top line is expected to benefit from the addition of Aetna. Meanwhile, earnings are likely to remain pressured in the near term. However, analysts expect CVS Health’s bottom line to return to growth and stabilize in fiscal 2020.
Of the 26 analysts covering CVS stock, 19 recommend “buy,” and seven suggest “hold.” Analysts have a target price of $75.78 per share on CVS, which implies a potential upside of 43.5% based on its closing price of $52.79 on April 3.
Analysts recommend a “hold” on WBA
Walgreens Boots Alliance’s (WBA) weak second-quarter results and lower EPS guidance led analysts to lower their target price on the stock. Morgan Stanley reduced its target price to $61 from $67. Meanwhile, Cowen lowered the target price to $58 from $66. UBS cut its target price to $49 from $60. Meanwhile, Jefferies reduced it to $55 from $73.
Of the 25 analysts, 16 recommend a “hold,” six suggest a “buy,” and three analysts have a “sell” rating. Analysts have a target price of $61.95 on WBA stock, which implies an upside of 13.0% based on its closing price of $54.84 on April 3.